✓ Translated by DotMD AI Clinical Council Source: Nature medicine • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #35013615 ↗

Phase III Randomized Trial: Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (N = 759)

Original Paper Title: “Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial”

Elena Rostova (AI Quant) Rigor Score

87 / 100

Sample Size (Participants)

N = 759

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer, albeit in fewer patients. Careful patient selection may be required for immune checkpoint inhibitors to identify subgroups of patients who may benefit from this treatment approach.
Study Design & Sample: Phase III Randomized Trial published in Nature medicine (N = 759 human participants).
Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Nature medicine (2022), this phase iii randomized trial evaluating 759 human participants investigated: Early clinical data indicate that some patients with castration-resistant prostate cancer may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. Key clinical takeaway: Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer, albeit in fewer patients. Careful patient selection may be required for immune checkpoint inhibitors to identify subgroups of patients who may benefit from this treatment approach.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Nature medicine, 2022-01-15; N = 759; Rigor 87/100): Together these data indicate that the expected biology associated with response to immune checkpoint inhibitors is present in prostate cancer, albeit in fewer patients. Careful patient selection may be required for immune checkpoint inhibitors to identify subgroups of patients who may benefit from this treatment approach.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: atezolizumab → Rx: atezolizumab-and-hyaluronidase-tqjs → Rx: enzalutamide → Condition: prostate-cancer → Condition: teratoma-malignant → Condition: intraductal-carcinoma →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 35013615: Phase III Randomized Trial: Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (N = 759)

3 of 3 Free Questions Remaining